pioglitazone has been researched along with Liver Neoplasms in 21 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 7.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 5.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 3.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| "Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging." | 2.84 | Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. ( Andreesen, R; Endlicher, E; Ghibelli, L; Hackl, C; Herr, W; Klebl, F; Reichle, A; Schulz, U; Vogelhuber, M; Walter, I; Wiedmann, K; Wiest, R, 2017) |
| "It also provides an overview of NAFLD agents currently under development." | 2.55 | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. ( Banini, BA; Sanyal, AJ, 2017) |
| "NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma." | 2.55 | Therapies in non-alcoholic steatohepatitis (NASH). ( Oseini, AM; Sanyal, AJ, 2017) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis." | 1.56 | Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer. ( Aoki, T; Bouvet, M; Fukuda, Y; Higuchi, T; Hoffman, RM; Inubushi, S; Murakami, M; Nishino, H; Singh, SR; Sugisawa, N; Tashiro, Y; Yamamoto, J, 2020) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 1.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| "NASH, however, may progress to liver cirrhosis with risk of liver cancer." | 1.38 | [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. ( Grønbæk, H; Heebøll, S; Kazankov, K; Poulsen, MK; Vilstrup, H, 2012) |
| "Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation." | 1.37 | Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. ( Borbath, I; Stärkel, P, 2011) |
| "Pioglitazone treatment was initiated the day after the first diethylnitrosamine injection." | 1.34 | The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. ( Borbath, I; Horsmans, Y; Leclercq, I; Moulin, P; Sempoux, C, 2007) |
| " Genes that are differentially expressed between the more toxic troglitazone/ciglitazone group and the less toxic rosiglitazone/pioglitazone group are involved in necrotic, apoptotic, and cell proliferative pathways." | 1.33 | Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. ( Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, S | 1 |
| He, K | 1 |
| Tian, C | 1 |
| Sun, H | 1 |
| Zhu, C | 1 |
| Bai, S | 1 |
| Liu, J | 1 |
| Wu, Q | 1 |
| Xie, D | 1 |
| Yue, T | 1 |
| Shen, Z | 1 |
| Dai, Q | 1 |
| Yu, X | 1 |
| Zhu, S | 1 |
| Liu, G | 1 |
| Zhou, R | 1 |
| Duan, S | 1 |
| Tian, Z | 1 |
| Xu, T | 1 |
| Wang, H | 1 |
| Bai, L | 1 |
| Tashiro, Y | 1 |
| Nishino, H | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Fukuda, Y | 1 |
| Yamamoto, J | 1 |
| Inubushi, S | 1 |
| Aoki, T | 1 |
| Murakami, M | 1 |
| Singh, SR | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Banini, BA | 1 |
| Sanyal, AJ | 2 |
| Walter, I | 1 |
| Schulz, U | 1 |
| Vogelhuber, M | 1 |
| Wiedmann, K | 1 |
| Endlicher, E | 1 |
| Klebl, F | 1 |
| Andreesen, R | 1 |
| Herr, W | 1 |
| Ghibelli, L | 1 |
| Hackl, C | 1 |
| Wiest, R | 1 |
| Reichle, A | 3 |
| Li, S | 1 |
| Ghoshal, S | 1 |
| Sojoodi, M | 1 |
| Arora, G | 1 |
| Masia, R | 1 |
| Erstad, DJ | 1 |
| Lanuti, M | 1 |
| Hoshida, Y | 1 |
| Baumert, TF | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Chongmelaxme, B | 1 |
| Phisalprapa, P | 1 |
| Sawangjit, R | 1 |
| Dilokthornsakul, P | 1 |
| Chaiyakunapruk, N | 1 |
| Li, LJ | 1 |
| Li, GD | 1 |
| Wei, HL | 1 |
| Chen, J | 1 |
| Liu, YM | 1 |
| Li, F | 1 |
| Xie, B | 1 |
| Wang, B | 1 |
| Li, CL | 1 |
| Yang, Y | 1 |
| Zhao, LH | 1 |
| Huang, B | 1 |
| Wang, RY | 1 |
| Yuan, SX | 1 |
| Tao, QF | 1 |
| Xu, Y | 1 |
| Sun, HY | 1 |
| Lin, C | 1 |
| Zhou, WP | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Oseini, AM | 1 |
| Shim, J | 1 |
| Kim, BH | 1 |
| Kim, YI | 1 |
| Kim, KY | 1 |
| Hwangbo, Y | 1 |
| Jang, JY | 1 |
| Dong, SH | 1 |
| Kim, HJ | 1 |
| Chang, YW | 1 |
| Chang, R | 1 |
| Borbath, I | 2 |
| Stärkel, P | 1 |
| Heebøll, S | 1 |
| Kazankov, K | 1 |
| Poulsen, MK | 1 |
| Vilstrup, H | 1 |
| Grønbæk, H | 1 |
| Kawai, D | 1 |
| Takaki, A | 1 |
| Nakatsuka, A | 1 |
| Wada, J | 1 |
| Tamaki, N | 1 |
| Yasunaka, T | 1 |
| Koike, K | 1 |
| Tsuzaki, R | 1 |
| Matsumoto, K | 1 |
| Miyake, Y | 1 |
| Shiraha, H | 1 |
| Morita, M | 1 |
| Makino, H | 1 |
| Yamamoto, K | 1 |
| Saha, S | 1 |
| Chan, DS | 1 |
| Lee, CY | 1 |
| Wong, W | 1 |
| New, LS | 1 |
| Chui, WK | 1 |
| Yap, CW | 1 |
| Chan, EC | 1 |
| Ho, HK | 1 |
| Plikat, K | 1 |
| Elmlinger, MW | 1 |
| Schölmerich, J | 1 |
| Füessl, HS | 1 |
| Guo, YT | 1 |
| Leng, XS | 1 |
| Li, T | 1 |
| Zhao, JM | 1 |
| Lin, XH | 1 |
| Vogt, T | 1 |
| Coras, B | 1 |
| Hafner, C | 1 |
| Landthaler, M | 1 |
| Guo, L | 1 |
| Zhang, L | 1 |
| Sun, Y | 1 |
| Muskhelishvili, L | 1 |
| Blann, E | 1 |
| Dial, S | 1 |
| Shi, L | 1 |
| Schroth, G | 1 |
| Dragan, YP | 1 |
| Leclercq, I | 1 |
| Moulin, P | 1 |
| Sempoux, C | 1 |
| Horsmans, Y | 1 |
3 reviews available for pioglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neopl | 2017 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agent | 2017 |
1 trial available for pioglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Topics: Administration, Metronomic; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols | 2017 |
17 other studies available for pioglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Galactosylceramides; Gene Expression Regulation; Hu | 2020 |
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer.
Topics: Animals; Colonic Neoplasms; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Li | 2020 |
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Choline; Diet, High- | 2019 |
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Live | 2019 |
Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Ce | 2014 |
Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Hep | 2015 |
The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; | 2010 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; | 2011 |
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Pioglitazone; Prognosis; | 2012 |
Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.
Topics: Animals; Disease Progression; Fatty Liver; Hydrogen; Hypoglycemic Agents; Liver Neoplasms; Male; Mic | 2012 |
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell P | 2012 |
[Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma].
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alky | 2003 |
[Fatty liver. Not only ultrasound to be relied on!].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep | 2003 |
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; | 2004 |
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecit | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Pro | 2006 |
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Topics: 2-Acetylaminofluorene; Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinogens; | 2007 |